According to a new research, the anti-Covid medication 2-DG developed by the DRDO is effective against all Covid-19 variations.
According to the findings, 2-DG inhibits SARS-CoV-2 proliferation and protects cells from infection-induced cytopathic effect (CPE) and cell death. According to the findings, the medication can be utilised as part of a therapy plan.
The chemical advanced to clinical trials in Covid patients based on these preliminary in-vitro findings.
The research, which was published on June 15, has yet to be peer-reviewed. Anant Narayan Bhatt, Abhishek Kumar, Yogesh Rai, Dhiviya Vedagiri, and others contributed to the script.
In May, the medication, produced by the Defence Research and Development Organisation (DRDO) and Dr Reddy’s Laboratories, was approved for treatment in moderate to severe Covid-19 patients.
2-DG has been shown in clinical studies to help hospitalised Covid-19 patients recover faster and minimise their reliance on supplemental oxygen. Dr. Reddy’s Laboratories has released 2-DG in sachet form.
The first batch of the oral drug was released on May 17
DRDO published instructions on the use of its 2-DG medication for Covid-19 patients two weeks ago, noting that caution should be used when administering this prescription to persons with comorbidities such uncontrolled diabetes, severe heart problems, or acute respiratory distress syndrome.
The Drugs Controller General of India (DCGI) authorised the medication produced by DRDO in cooperation with Dr Reddy’s Laboratories in Hyderabad last month for emergency use as an additional therapy in moderate to severe coronavirus patients.
The medication comes in powder form in a sachet and may be used orally after being dissolved in water. It is available for Rs 990 per sachet.
Clinical study data suggests that the chemical aids in the quicker recovery of patients hospitalised with Covid-19 and lowers their need on supplemental oxygen, according to the government.
